DESI NDA withdrawal
FDA announced it is withdrawing approval of NDAs for certain single-entity coronary vasodilators containing pentaerythritol tetranitrate (PETNI since they lack substantial evidence of effectiveness for the prophylactic treatment of angina pectoris. Notice does not apply to nine products for which a hearing was requested.
You may also be interested in...
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.